Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, February 1, 2022
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
Mon, January 31, 2022
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
[ Mon, Jan 31st 2022
] - WOPRAI
Joseph Pantginis Maintained (CAPR) at Strong Buy with Increased Target to $18 on, Jan 31st, 2022
Joseph Pantginis of HC Wainwright & Co., Maintained "Capricor Therapeutics, Inc." (CAPR) at Strong Buy with Increased Target from $14 to $18 on, Jan 31st, 2022.
Joseph, nor any peers, have made any analyst calls on CAPR in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30